The 5-HT$_{1B}$ receptor - a potential target for antidepressant treatment

Mikael Tiger$^{1,2}$ · Katarina Varnäs$^1$ · Yoshiro Okubo$^2$ · Johan Lundberg$^1$

Received: 26 October 2017 / Accepted: 26 February 2018 / Published online: 15 March 2018
© The Author(s) 2018

Keywords 5-HT$_{1B}$ receptors · Serotonin · Depression · Antidepressants

Abstract
Major depressive disorder (MDD) is the leading cause of disability worldwide. The serotonin hypothesis may be the model of MDD pathophysiology with the most support. The majority of antidepressants enhance synaptic serotonin levels quickly, while it usually takes weeks to discern MDD treatment effect. It has been hypothesized that the time lag between serotonin increase and reduction of MDD symptoms is due to downregulation of inhibitory receptors such as the serotonin 1B receptor (5-HT$_{1B}$R). The research on 5-HT$_{1B}$R has previously been hampered by a lack of selective ligands for the receptor. The last extensive review of 5-HT$_{1B}$R in the pathophysiology of depression was published 2009, and based mainly on findings from animal studies. Since then, selective radioligands for in vivo quantification of brain 5-HT$_{1B}$R binding with positron emission tomography has been developed, providing new knowledge on the role of 5-HT$_{1B}$R in MDD and its treatment. The main focus of this review is the role of 5-HT$_{1B}$R in relation to MDD and its treatment, although studies of 5-HT$_{1B}$R in obsessive-compulsive disorder, alcohol dependence, and cocaine dependence are also reviewed. The evidence outlined range from animal models of disease, effects of 5-HT$_{1B}$ receptor agonists and antagonists, case-control studies of 5-HT$_{1B}$R receptor binding postmortem and in vivo, with positron emission tomography, to clinical studies of 5-HT$_{1B}$R receptor effects of established treatments for MDD. Low 5-HT$_{1B}$R binding in limbic regions has been found in MDD patients. When 5-HT$_{1B}$R ligands are administered to animals, 5-HT$_{1B}$R agonists most consistently display antidepressant-like properties, though it is not yet clear how 5-HT$_{1B}$R is best approached for optimal MDD treatment.

Introduction
Major depression is a significant contributor to the global burden of disease, and likely the leading cause of disability in the industrialized world (Whiteford et al. 2013). Although major depressive disorder (MDD) is a highly treatable condition, half of the patients fail to respond to treatment with a selective serotonin reuptake inhibitor (SSRI), the first line of pharmacological treatment for MDD. Furthermore, with most antidepressants there is a lag time of weeks between initiation of treatment and significant antidepressant effect (Gelenberg and Chesen 2000). A majority of drugs for depression target the serotonin system with increased serotonin concentrations as a common effect, which has been the main rationale for the serotonin hypothesis of depression, stating that depression may be due to serotonin deficiency in the brain (Lapin and Oxenkrug 1969). In the absence of noninvasive methods to directly assess brain serotonin levels, in vivo confirmatory support for this hypothesis is lacking. However, recent molecular imaging techniques allowing for the study of brain neurotransmitter receptors in vivo have provided new knowledge regarding the involvement of receptors for serotonin in the pathophysiology and treatment of MDD.

Since the serotonin-enhancing effect of antidepressants such as SSRI has a rapid onset (Rothman and Baumann 2002), it has been suggested that subsequent downstream receptor regulation might be important for the antidepressant effect (Nutt 2002). Out of the 14 receptors for serotonin (5-hydroxytryptamine, 5-HT), the inhibitory 5-hydroxytryptamine$_{1A}$ (5-HT$_{1A}$) and 5-hydroxytryptamine$_{1B}$
5-HT1A and 5-HT1B receptors display 43% amino acid sequence homology and belong to the same family of G protein-coupled receptors (Hoyer et al. 2002). Importantly, the receptor subtypes display distinct cellular localizations, with 5-HT1A receptors being confined to somata and dendrites (Sotelo et al. 1990), and 5-HT1B receptors localized predominantly in axon terminals (Boschert et al. 1994). Activation of 5-HT1A and 5-HT1B receptors in serotonergic neurons thereby serves to regulate extracellular 5-HT levels by different mechanisms, i.e., by controlling neuronal firing rate (Sprouse and Aghajanian 1987) and by modulating transmitter release (Engel et al. 1986; Middlemiss 1984), respectively. In addition, notable differences in the distribution of postsynaptic 5-HT1A and 5-HT1B receptors in nonserotonergic neurons further support distinct functional roles of these receptors. While 5-HT1A receptors are abundantly localized in cortical regions (Hall et al. 1997), 5-HT1B receptors are widely distributed in the brain, showing particularly high density in the basal ganglia (see “5-HT1B receptor brain distribution” section).

The role of 5-HT1A receptors in the pathophysiology and treatment of depression has been thoroughly investigated (Savitz et al. 2009). However, research on 5-HT1B receptors has earlier been hampered by a lack of selective ligands (Barnes and Sharp 1999; Middlemiss and Hutson 1990). Recent development of compounds with 5-HT1B receptor selectivity has paved the way for exploration of the role of 5-HT1B receptors in MDD (Slasić 2002; Zimmer and Le Bars 2013).

This is a review of the relevance of 5-HT1B receptors in psychiatric disorders, especially in MDD. Thorough literature searches applying MeSH terms have been conducted in PubMed, on “5-HT1B receptor AND depression,” “5-HT1B receptor AND anxiety,” “5-HT1B receptor AND aggression,” “5-HT1B receptor AND alcohol,” and “5-HT1B receptor AND cocaine,” for an overview of the field.

5-HT1B receptor structure and intracellular function

The 5-HT1B receptor has a putative seven transmembrane spanning structure (Saudou and Hen 1994) and is G-protein coupled (Barnes and Sharp 1999; Hamblin et al. 1987), inhibiting adenylate cyclase as demonstrated with reduced forskolin-stimulated cAMP release upon agonist binding (Adham et al. 1992; Levy et al. 1992a; Weinshank et al. 1992). The gene coding for the mouse 5-HT1B receptor is located on chromosome 9 (position 9E), and the human 5-HT1B receptor gene is located on chromosome 6 (6q13) (Saudou and Hen 1994). The amino acid sequence of the 5-HT1B receptor gene is to a high degree similar for humans and rodents, with 93% overall homology and 96% homology in transmembrane regions (Adham et al. 1992; Maroteaux et al. 1992; Voigt et al. 1991). Despite this genetic similarity, the species variants of 5-HT1B receptors display some distinct differences in drug affinity, with higher affinity for the selective 5-HT1B/1D receptor agonist sumatriptan and lower affinity for β-adrenergic receptor antagonists such as pindolol and propranolol for the human 5-HT1B receptor compared to rodent variants (Adham et al. 1992; Demyshyn et al. 1992; Hamblin et al. 1992; Jin et al. 1992; Levy et al. 1992b; Weinshank et al. 1992; Voigt et al. 1991). This species difference seems mainly conferred by a single amino acid. Replacement of threonine at residue 355, on the seventh transmembrane segment, with the corresponding asparagine in rodents renders the human 5-HT1B receptor essentially the same pharmacological properties as the rodent receptor (Metcalf et al. 1992; Oksenberg et al. 1992; Parker et al. 1993).

5-HT1B receptor distribution and function

The 5-HT1B receptor is involved in a broad repertoire of physiological effects, including satiety (Voigt and Fink 2015), sleep (Boutrel et al. 1999), locomotor activity (Chaoulouf et al. 1999; Cheetham and Heal 1993; Ramboz et al. 1996), sexual behavior and ejaculatory function (Giuliano 2007; Rodriguez-Manzo et al. 2002), reduction of body temperature (Hagan et al. 1997), and modulation of memory and learning (Buhot et al. 2000). The main body of the 5-HT1B receptor literature relates to its potential role in psychiatric disorders, which will be outlined in more detail in “The involvement of 5-HT1B receptors in behaviors relevant to psychiatry” section. The cellular localization of 5-HT1B receptors is mainly presynaptic, with receptors distributed primarily to axon terminals, as demonstrated with autoradiography, lesion studies, immunocytochemistry, and viral transfection studies (Boschert et al. 1994; Bruinvels et al. 1994; Sari 2004; Varnas et al. 2005). Depending on localization, 5-HT1B receptors may act as autoreceptors, inhibiting serotonin release (Barnes and Sharp 1999; Brazell et al. 1985; Buhlen et al. 1996; Davidson and Stamford 1995; De Groote et al. 2003; Engel et al. 1986; Hjorth and Tao 1991; Limberger et al. 1991; Martin et al. 1992; Middlemiss 1984; Rutz et al. 2006; Schlicker et al. 1997; Sharp et al. 1989; Starkey and Skingle 1994), or as heteroreceptors, regulating the release of other transmitters (Barnes and Sharp 1999; Ruf and Bhagwagar 2009; Sari 2004).
5-HT<sub>1B</sub> autoreceptors

In the serotonin projection areas, the role of 5-HT<sub>1B</sub> receptors in regulation of 5-HT release is relatively straightforward, and inhibitory. Upon binding to the 5-HT<sub>1B</sub> receptors, 5-HT inhibits formation of cAMP and downstream cellular responses. This results in diminished transmitter release (Barnes and Sharp 1999; Leenders and Sheng 2005; Middlemiss and Hutson 1990). More recent research supports that the 5-HT<sub>1B</sub> receptors can regulate serotonin transporter function, thus serving as an additional mechanism by which 5-HT<sub>1B</sub> autoreceptors modulate extracellular transmitter levels in serotonergic projection regions (Hagan et al. 2012; Montanez et al. 2014). Administration of the 5-HT<sub>1B</sub> receptor agonist CP-93,129 suppressed 5-HT release in the hippocampus in rats (Hjorth and Tao 1991). In wild-type mice, 5-HT<sub>1B</sub> receptor agonist-induced decrease and 5-HT<sub>1B</sub> receptor antagonist-induced increase of 5-HT in the hippocampus and cortex has been demonstrated, whereas no effects were found in 5-HT<sub>1B</sub> receptor gene knockout mice (Rutz et al. 2006).

In the raphe nuclei, the regulation of the serotonin system by 5-HT<sub>1B</sub> receptors is more complex (Sari 2004). Local perfusion with the 5-HT<sub>1B</sub> receptor agonist CP-93,129 decreased 5-HT release in the dorsal and median raphe nucleus in rats (Adell et al. 2001). In the same study with local perfusion of another 5-HT<sub>1B</sub> Receptor agonist CP-94,253, a biphasic effect on 5-HT release was found in the median raphe nucleus, with 5-HT reductions at low doses and increase of 5-HT at a high dose of CP-94,253 (Adell et al. 2001). The biphasic regulation of 5-HT release may suggest the presence of 5-HT<sub>1B</sub> receptors both in serotonin neurons and inhibitory neurons controlling the release of 5-HT in the median raphe nuclei (Adell et al. 2001; Bagdy et al. 2000).

Recent studies in mouse models developed for tissue-specific regulation of 5-HT<sub>1B</sub> expression have provided further insight regarding the functional role of 5-HT<sub>1B</sub> autoreceptors. Selective knockdown of the 5-HT<sub>1B</sub> autoreceptors was found to increase extracellular 5-HT levels in response to an SSRI and to induce antidepressant-like phenotypes, thus supporting the potential benefit of pharmacological inhibition of these receptors for treatment of depression (Nautiyal et al. 2016). The role of 5-HT<sub>1B</sub> receptor antagonists in the treatment of depression will be further described in the “Effects of agonists and antagonists in animal models of depression” section.

5-HT<sub>1B</sub> heteroreceptors

With 5-HT<sub>1B</sub> receptors located on nonserotonergic neurons regulation of the release of glutamate, GABA, acetylcholine, and dopamine has been demonstrated (Ruf and Bhagwagar 2009). There is some, but relatively sparse, data on the effect of 5-HT<sub>1B</sub> receptors on glutamate, the major excitatory transmission system in the brain. A subpopulation of 5-HT<sub>1B</sub> receptors were shown to be colocalized with the AMPA receptor subunit GluR2 in hippocampal dentate gyrus in rats, as visualized with immunofluorescence in dendrites (Peddie et al. 2010). Recently, our group reported a correlation between 5-HT<sub>1B</sub> receptor binding and glutamatergic N-methyl-D-aspartate receptor binding in layers I–III of the anterior cingulate cortex (ACC) of human postmortem tissue (Veldman et al. 2017). Functionally, there are indirect signs of decreased glutamate release by presynaptic 5-HT<sub>1B</sub> Receptors, with selectively reduced amplitude of evoked excitatory postsynaptic currents in the bed nucleus of the stria terminalis (BNST) by the 5-HT<sub>1B</sub> the receptor agonist CP93,129 (Guo and Rainnie 2010).

There are more data supporting a role of 5-HT<sub>1B</sub> receptors in regulating inhibitory transmitter systems. A number of studies demonstrate an inhibitory effect of the 5-HT<sub>1B</sub> receptor on the main inhibitor in the brain, gamma-aminobutyric acid (GABA). The 5-HT<sub>1B/1D</sub> receptor agonist sumatriptan inhibited GABA release in the neocortex (Feuerstein et al. 1996). Inhibition of GABA-induced inhibitory postsynaptic currents (IPSCs) by 5-HT<sub>1B</sub> receptors has been demonstrated with patch clamp recordings in substantia nigra, suprachiasmatic nuclei, subthalamic nucleus, and globus pallidus (Bramley et al. 2005; Chen et al. 2008; Ding et al. 2015; Hashimoto and Kita 2008; Shen and Johnson 2008; Stanford and Lacey 1996). There is also immunohistochemical evidence of 5-HT<sub>1B</sub> acting as a heteroreceptor on the GABA system, with a majority of GABA-positive neurons in the inferior colliculus also being positive for the 5-HT<sub>1B</sub> receptor (Peruzzi and Dut 2004).

Furthermore, 5-HT<sub>1B</sub> receptors on cholinergic neurons inhibit acetylcholine release in the ventral striatum (Virk et al. 2016) and hippocampus (Cassel et al. 1995; Maura and Raiteri 1986). In a microdialysis study, administration of the 5-HT<sub>1B</sub> receptor antagonist NAS-181 increased acetylcholine levels profoundly in the frontal cortex and hippocampus, and based on this finding the authors suggested that acetylcholine release in these brain regions is under tonic inhibitory control by 5-HT<sub>1B</sub> receptors (Hu et al. 2007).

Dopaminergic neurons are also regulated by 5-HT<sub>1B</sub> receptors, with mostly increased dopamine release upon receptor activation in nigrostrial, mesolimbic, and mesocortical pathways, as previously reviewed (Alex and Pehek 2007). Given the G<sub>i</sub> protein-coupled inhibitory function of 5HT<sub>1B</sub> receptors and the absence of 5-HT<sub>1B</sub> receptor mRNA expression on dopaminergic neurons in the substantia nigra, and ventral tegmentum (Bruinvels et al. 1994; Sari et al. 1999; Varnas et al. 2005), it is not likely that the facilitative effect on dopamine transmission is mediated by 5-HT<sub>1B</sub> receptors residing on dopaminergic neurons. More plausible instead is indirect 5-HT<sub>1B</sub> receptor action on dopaminergic neurons, via inhibition of dopamine restricting GABAergic interneurons in ventral...
5-HT$_{1B}$ receptor brain distribution

The distribution of 5-HT$_{1B}$ receptors in the brain has been mapped with autoradiography (Fig. 1). In humans, high 5-HT$_{1B}$ receptor densities have been found in the substantia nigra and globus pallidus (Bonaventure et al. 1997; Varnas et al. 2001). Intermediate densities of 5-HT$_{1B}$ receptors were found in the striatum, with higher binding in ventromedial parts, the dorsal raphe nucleus, and the cerebral cortex, although there was a subregion within the medial occipital cortex with denser labeling (Varnas et al. 2001; Varnas et al. 2004). Lower 5-HT$_{1B}$ receptor binding was found in the hippocampus and the amygdala (Varnas et al. 2001). Low 5-HT$_{1B}$ receptor density was observed in the thalamus and very low (Varnas et al. 2001) or no (Bonaventure et al. 1997). 5-HT$_{1B}$ receptor binding was found in the cerebellum. This rank order of 5-HT$_{1B}$ receptor brain distribution has been confirmed in vivo with positron emission tomography (PET) (Fig. 2) and the 5-HT$_{1B}$ receptor selective radioligand $[^{11}C]$ AZ10419369 (Varnas et al. 2011). It is homologous with the distribution in rodents, with high 5-HT$_{1B}$ receptor levels in substantia nigra and globus pallidus (Bruinvels et al. 1993; Langlois et al. 1995) and intermediate levels in the striatum (Bruinvels et al. 1993).

Regional 5-HT$_{1B}$ receptor protein synthesis in the brain has been mapped with in situ hybridization histochemistry, with antisense-RNA probes to determine regional mRNA expression. In most examined regions in humans, mRNA expression levels matched the reported distribution of 5-HT$_{1B}$ receptors, with relatively high expression in the caudate nucleus, putamen, ventral striatum, cerebral cortex, and rostral raphe nuclei (Bidmon et al. 2001; Jin et al. 1992; Varnas et al. 2005). However, there was a distinct mismatch in the globus pallidus and substantia nigra, 5-HT$_{1B}$ receptor-rich regions where no 5-HT$_{1B}$ receptor mRNA expression was found. Absence of 5-HT$_{1B}$ receptor mRNA expression in the globus pallidus and...
substantia nigra despite high 5-HT1B receptor densities in these regions appears across species, reported in rodents as well as guinea pigs (Bonaventure et al. 1998; Boschert et al. 1994). This mismatch, with high 5-HT1B receptor levels not accompanied by corresponding regional protein synthesis, is one in a line of evidences of axon terminal localization of the 5-HT1B receptor (Sari 2004; Varnas et al. 2005).

When interpreting imaging findings based on studies with 5-HT1B receptor radioligands, it is important to note that the radioligands do not distinguish between the functionally different autoreceptors and heteroreceptors localized in serotonergic and nonserotonergic neurons. However, given the abundant 5-HT1B mRNA expression in forebrain regions having high receptor density, it is likely that the heteroreceptor population represents a notable proportion of forebrain 5-HT1B receptors. A major contribution of the heteroreceptors to the signal of 5-HT1B receptor radioligands is further supported by recent findings of markedly reduced binding after selective knockdown of 5-HT1B heteroreceptors in mice (Nautiyal et al. 2015). By contrast, neurotoxic lesioning of serotonergic neurons (Compan et al. 1998) or selective ablation of 5-HT1B autoreceptors (Nautiyal et al. 2015) has no detectable effect on radioligand binding, suggesting that the autoreceptor component represents a minor proportion of forebrain 5-HT1B receptors.

The relationship of the 5-HT1B receptor to p11

5-HT1B receptor function and distribution is intimately linked to the intracellular protein p11 (SI00A10) (Svenningsson et al. 2006). p11 is required for translocation to the plasma membrane of a number of intracellular proteins, such as Annexin II (Deora et al. 2004), the sodium channel NaV1.8/SNS (Okuse et al. 2002), the calcium channels TRPV5 and TRPV6 (van de Graaf et al. 2003), and the potassium channel TASK-1 (Girard et al. 2002). Trafficking of 5-HT1B receptors to the plasma membrane is also dependent on p11, with two-fold higher surface receptor portions in COS-7 cells cotransfected with p11 compared to cells only transfected with 5-HT1B receptors (Svenningsson et al. 2006). Moreover, the inhibitory effect of serotonin on forskolin-induced cAMP formation was significantly enhanced in p11 cotransfected cells (Svenningsson et al. 2006). In line with this, absence of p11, as demonstrated in a p11 gene knockout mouse model, resulted in low 5-HT1B receptor binding in the globus pallidus and substantia nigra (Svenningsson et al. 2006). In the p11 knockout mice, 5-HT1B receptor agonist-induced cortical downregulation of phospho-Thr202-Tyr204-ERK1/2 was lost and inhibition of cAMP formation upon 5-HT1B receptor agonist administration was reduced, as demonstrated with phospho-Ser10-synapsin I levels in striatum (Svenningsson et al. 2006). Furthermore, interaction between p11 and 5-HT1B receptors has been confirmed with Western blotting, where coimmunoprecipitation was found in HeLa cells and mouse brain tissue (Svenningsson et al. 2006). Colocalization of p11 and 5-HT1B receptors at the cell surface has been demonstrated with immunofluorescence staining (Svenningsson et al. 2006). Moreover, in mouse brain distribution of mRNA expression is remarkably similar for p11 and 5-HT1B receptors (Svenningsson et al. 2006). This impression has been confirmed with immunohistochemically labeled cells, where p11 and 5-HT1B receptors were coexpressed in the striatum, hippocampus, and cingulate cortex (Egeland et al. 2011). In humans, significant correlations between p11 and 5-HT1B receptor mRNA levels in the orbitofrontal cortex, frontopolar cortex, and hippocampus postmortem have been reported in suicide subjects as well as controls (Anisman et al. 2008). Thus, p11 plays an important role in 5-HT1B receptor expression and function; although this interaction is not specific, p11 also modulates surface expression and function of the 5-HT4 receptor (Warner-Schmidt et al. 2009) and mGluR5 (metabotropic glutamate receptor 5 (Lee et al. 2015)).

The involvement of 5-HT1B receptors in behaviors relevant to psychiatry

5-HT1B receptors in relation to psychiatry

Knockout of the 5-HT1B receptor gene results in mice with a distinct behavioral phenotype, aggressive and less cautious (Saudou et al. 1994; Zhuang et al. 1999). Decreased anxiety in the 5-HT1B receptor knockout mice has consequently been reported, with low anxiety in the elevated plus maze and more activity in the open field (Brunner et al. 1999; Nautiyal et al. 2016; Zhuang et al. 1999). In line with this, overexpression of 5-HT1B receptors in the dorsal raphe nucleus has yielded increased stress-induced anxiety in rats (Clark et al. 2002). In contrast, the 5-HT1B receptor-overexpressing rats displayed less anxiety, before exposure to stress (Clark et al. 2002). Furthermore, in nonstressed rats, there was an inverse correlation between 5-HT1B receptor mRNA expression in dorsal raphe nucleus and anxiety, as estimated with activity in the elevated plus maze (Kaiyala et al. 2003). In serotoninergic projection areas in the brain, high 5-HT1B receptor density has been reported in a genetic mouse model for anxiety (Clement et al. 1996).

Another major source of information about the behavioral effects of 5-HT1B receptors stems from extrapolation of the effects of 5-HT1B receptor ligands. Most reports describe anxiogenic effects of 5-HT1B receptor agonists (Sari 2004), with increased anxiety in paradigms as the elevated plus-maze (Lin and Parsons 2002; Solati et al. 2011). Sari hypothesized that 5-HT1B receptors modulate anxiety through inhibition of serotonin, acetylcholine, and GABA (Sari 2004). However, anxiolytic properties of 5-HT1B receptor agonists...
have also been reported. The early reports on reduced anxiety upon 5-HT\textsubscript{1B} receptor activation have been dismissed as results of nonselective ligands (Sari 2004). Still, reduced anxiety-related behavior has been demonstrated with CP-94,253, a selective 5-HT\textsubscript{1B} receptor agonist, in the Vogel conflict drinking test, which is sensitive to the acute anxiolytic effects of benzodiazepines, but fail to detect SSRI effect (Chojnacka-Wojcik et al. 2005). Furthermore, CP-94,253 attenuated the anxiogenic effects of cocaine (Klein et al. 2016), while the 5-HT\textsubscript{1B} receptor antagonist increased cocaine-induced anxiety (Hoplight et al. 2005). Otherwise, in baseline conditions, the effect of 5-HT\textsubscript{1B} receptor antagonists is more clear and consequent. Anxiolytic properties of 5-HT\textsubscript{1B} receptor antagonists has been demonstrated in a variety of paradigms for anxiety such as Vogel drinking test (Chojnacka-Wojcik et al. 2005), separation-induced vocalization (Dawson et al. 2006; Hudzik et al. 2003; Zhang et al. 2011), human threat test (Dawson et al. 2006), and reactions to a novel environment (Nowicki et al. 2014). In humans, studies on the role of 5-HT\textsubscript{1B} receptors in anxiety are disproportionately sparse. Increased fear of public speaking has been reported in healthy volunteers after administration of the 5-HT\textsubscript{1B/D} receptor agonist sumatriptan (de Rezende et al. 2016). Still, the 5-HT\textsubscript{1B} receptor in anxiety, though human studies are sparse and inconclusive.

5-HT\textsubscript{1B} receptors in relation to depressive states

Depression is the psychiatric condition with most reports in the literature in relation to the 5-HT\textsubscript{1B} Receptor. A large part of previous 5-HT\textsubscript{1B} receptor depression research stems from preclinical studies, mostly in rodents (Ruf and Bhagwagar 2009). Mice constitutionally or conditionally genetically deprived of 5-HT\textsubscript{1B} receptors not only are less anxious, but also show less depression-like behavior, with less immobility time in both the forced swim test (FST) and the tail suspension test (TST) (Jones and Lucki 2005; Nautiyal et al. 2016), and higher sucrose preference (Bechtholt et al. 2008; Nautiyal et al. 2016). Jones and Lucki found significantly lower immobility time only in female 5-HT\textsubscript{1B} receptor knockout mice compared to wild-type mice. Furthermore, in a number of microdialysis studies, an augmentation of serotonin levels in response to SSRI was found in the hippocampus (Knobelmann et al. 2001; Malagie et al. 2001; Nautiyal et al. 2016), but not in the striatum (De Groote et al. 2003; Knobelmann et al. 2001) of 5-HT\textsubscript{1B} receptor knockout mice compared with controls. The regional difference in SSRI-induced serotonin release may be due to innervation, with hippocampus receiving serotonin input mainly from the 5-HT\textsubscript{1B} receptor key region the median raphe nucleus, while the striatum receives projections from the dorsal raphe nucleus (Knobelmann et al. 2001; Tork 1990). By contrast, the knockout for the 5-HT\textsubscript{1B} receptor-related p11 gene has resulted in a depressive phenotype, with more immobility time and lower preference to sucrose than wild-type littermates (Svenningsson et al. 2006). On the other hand, 5-HT\textsubscript{1B} Receptor binding in the p11 knockout mice is reduced, but not depleted (Svenningsson et al. 2006). This more moderate reduction in 5-HT\textsubscript{1B} receptor levels would be in line with human case-control studies, in which globally low brain binding and mRNA expression has been found in patients with...
major depressive disorder (MDD) (Tiger et al. 2016) and suicide subjects (Anisman et al. 2008), respectively. The behavioral consequences of having low versus no 5-HT\textsubscript{1B} receptors in the brain may differ considerably.

**Animal models**

The results from studies of 5-HT\textsubscript{1B} receptors in animal models for depression are largely inconclusive. Low 5-HT\textsubscript{1B} receptor binding has been demonstrated in the hippocampus in a rat model for inherited depressive traits, Flinder’s sensitive line, and in rats separated from their mothers. The effects of either genetic or environmental vulnerability for depression on 5-HT\textsubscript{1B} receptor binding could be reversed with antidepressants (Shrestha et al. 2014). Likewise, in Rgs2-mutant mice, with long latency to eat in the novelty suppressed feeding test as the main behavioral proxy for depressed mood, raphe nuclei 5-HT\textsubscript{1B} receptor gene expression was low (Lifschytz et al. 2012). On the other hand, higher 5-HT\textsubscript{1B} receptor densities in most brain regions, including dorsal hippocampus and the rostral raphe nuclei, were reported in Flinder’s sensitive line rats, both compared with Flinder’s resistant line and Sprague-Dawley rats (Nishi et al. 2009). Furthermore, an early finding in the field was the twofold higher 5-HT\textsubscript{1B} receptor binding in the cortex, hippocampus, and septum in rats that reacted with learned helplessness in reaction to uncontrollable electric shocks versus nonhelpless rats (Edwards et al. 1991). To complicate things further, high 5-HT\textsubscript{1B} receptor mRNA in dorsal raphe nucleus has been reported both in rats with learned helplessness (Neumaier et al. 1997) as well as in stress-resilient rats (Neumaier et al. 2002).

**Effects of agonists and antagonists in animal models of depression**

The role of the 5-HT\textsubscript{1B} receptor in depression-like states is more clearly disentangled in studies with drugs targeting the receptor. Blocking the inhibitory 5-HT\textsubscript{1B} receptor would in theory lead to increased levels of extracellular serotonin, and potential antidepressant effects. Indeed, treatment with the 5-HT\textsubscript{1B/1D} receptor antagonist GR 127935 increased latency to immobility in guinea pigs in FST (Rex et al. 2008). However, in most studies of 5-HT\textsubscript{1B} receptor antagonism in depression-like states, effect has been demonstrated only with simultaneous administration of antidepressant drugs (Ruf and Bhagwagar 2009). 5-HT\textsubscript{1B} receptor antagonists have been found to increase the anti-immobility effect in FST when coadministered with tricyclic antidepressants or a monoamine oxidase inhibitor (Chenu et al. 2008; Tatarczynska et al. 2004a) or with an SSRI (Tatarczynska et al. 2002). However, the 5-HT\textsubscript{1B/1D} receptor antagonist GR 127935 has also been reported to block the effects of paroxetine and imipramine in mice in the tail suspension test (O’Neill et al. 1996), whereas in the same study, depression-like immobility was decreased and the antidepressant effect of imipramine was increased with the 5-HT\textsubscript{1B} receptor agonist RU 24969 (O’Neill et al. 1996). Furthermore, reduced depression-like behavior has been demonstrated with different 5-HT\textsubscript{1B} receptor agonists also in the forced swimming test (Chenu et al. 2008; Tatarczynska et al. 2004b). The findings that antidepressant-like effects can be obtained with both antagonists and agonists targeting the receptor likely reflect the heterogeneous localization of 5-HT\textsubscript{1B} Receptors in different neuronal populations where autoreceptors and heteroreceptors may differently modulate depression-like behaviors (Chenu et al. 2008; Nautiyal et al. 2016).

**Human studies of 5-HT\textsubscript{1B} receptors in MDD**

Even though preclinical studies have had immense importance for the literature on 5-HT\textsubscript{1B} receptors in depression, translation of animal data to the clinical diagnosis MDD poses several challenges. Although animal models of depression are sensitive to antidepressants, none of them reflect the episodic feature of MDD and the most ominous MDD symptom, suicidal ideation, is absent in other species than humans. While some animal models may mimic vulnerability to stress and thereby the characteristic disproportionate load of symptoms such as lowered mood in MDD, no model convincingly displays signs of the symptoms that may persist also without precipitating external causes (Belmaker and Agam 2008). That said, it is also challenging to validly study the pathophysiology of major depressive disorder also in clinical studies, mainly due to difficulties in defining the diagnosis. The main shortcomings of the MDD definitions in the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM), the most widely used MDD definition, as well as in ICD-10, is the heterogeneity of the current MDD diagnosis, which can be fulfilled in 1497 different ways (Ostergaard et al. 2011), and the disregard of current psychosocial situation. Evaluating depressive symptoms in relation to current context is most probably necessary to avoid erroneously labeling stressed subjects as depressed (Horwitz and Wakefield 2007). These flaws in the current definition of MDD may have hampered the research on pathophysiology in MDD and may explain some of the inconsistent results. Still, in the emerging picture of accumulating 5-HT\textsubscript{1B} receptor MDD data, the 5-HT\textsubscript{1B} serotonin receptor subtype seems relatively consistently associated with or altered in this disorder. In a study of 394 psychiatric patients, an association between the silent G861C 5-HT\textsubscript{1B} receptor polymorphism, which is associated with low 5-HT\textsubscript{1B} Receptor brain density (Huang et al. 1999), and a history of MDD or substance abuse disorder was found (Huang et al. 2003). Moreover, there is indirect neuroendocrine evidence for altered 5-HT\textsubscript{1B} receptor function in MDD, with blunted growth hormone (GH) response to the
5-HT$_{1B/1D}$ receptor agonist sumatriptan in MDD patients (Cleare et al. 1998) and likewise reduced GH response to another triptan, zolmitriptan, which passes the blood brain barrier to a higher degree than sumatriptan, in a subpopulation of MDD patients with melancholic depression (Whale et al. 2001).

Comparisons of 5-HT$_{1B}$ Receptor measurements in subjects with MDD with those of controls are fundamental for knowledge about this receptor in the pathophysiology of MDD. At present, information regarding 5-HT$_{1B}$ receptor-related measures are available from studies of mRNA expression postmortem in forebrain regions (Anisman et al. 2008; Lopez-Figueroa et al. 2004) as well as PET studies of radioligand binding in vivo (Murrough et al. 2011b; Tiger et al. 2016).

PET offers molecular imaging of the living human brain at high anatomical resolution (Farde 1996). Brain PET requires a lipophilic ligand that can be labeled with a radioactive isotope and bind selectively to a target protein such as the 5-HT$_{1B}$ receptor (Hallidin et al. 2001). Tracer doses of the radioligand are injected intravenously, and a small portion passes the blood-brain barrier and bind to the target protein. The radioligand emits positrons that after a short distance form particle pairs with electrons. The particle pairs are annihilated and transformed into photons that traverse the skull and subsequently are detected by the surrounding PET system, enabling quantification of target protein binding in vivo in the brain. At present, there are two radioligands available for 5-HT$_{1B}$ receptor imaging in humans: [¹¹C]P943 and [¹¹C]AZ10419369 (Zimmer and Le Bars 2013). Both [¹¹C]AZ10419369 and [¹¹C]P943 have high affinity for 5-HT$_{1B}$ receptors ($K_D = 0.4$ and $K_D = 1.2$ nM, respectively) (Paterson et al. 2013). Despite the methodological differences and the small number of cases and controls, previous postmortem and in vivo studies consistently support a trend of low levels of cerebral 5-HT$_{1B}$ receptor related measures in unmedicated MDD subjects (Anisman et al. 2008; Murrough et al. 2011b; Tiger et al. 2016).

Interestingly, the pattern of low 5-HT$_{1B}$ receptors appears to be most prominent in the limbic cortices, in regions of reported relevance for MDD, such as the anterior cingulate cortex and hippocampus (Mayberg 1997; Steele et al. 2007). Low 5-HT$_{1B}$ Receptor binding has been measured with PET in the anterior cingulate cortex (ACC), both in patients with recurrent MDD (Tiger et al. 2016) and in patients with MDD and posttraumatic stress syndrome comorbidity (Murrough et al. 2011a) (Table 1). Moreover, lower p11 mRNA and protein levels in MDD patients compared with controls have been found postmortem in ACC, a region with distinct coexpression of p11 and 5-HT$_{1B}$ receptors (Egeland et al. 2011). However, in a recent [³H]AZ10419369 postmortem study allowing antidepressant medication MDD patients did not differ from controls in 5-HT$_{1B}$ receptor binding in pregenual ACC (Veldman et al. 2017). The absence of difference in 5-HT$_{1B}$ receptor binding in MDD in this autoradiography study could possibly be explained by pharmacological increase in 5-HT$_{1B}$ receptor $B_{ND}$, as has been demonstrated in cortical regions after SSRI in healthy subjects (Nord et al. 2013), canceling out any low 5-HT$_{1B}$ receptor binding in MDD patients. Furthermore, despite antidepressant treatment in 10 out of 12 patients, the MDD group stood out with low 5-HT$_{1B}$ receptor binding in females compared with males, in contrast with the control group and patients with schizophrenia and bipolar disorder, respectively (Veldman et al. 2017).

Likewise, in the hippocampus, 5-HT$_{1B}$ receptor binding was low in recurrent MDD as measured in vivo with PET (Tiger et al. 2016), and in patients with comorbidity of PTSD and MDD (Murrough et al. 2011a), and mRNA expression was numerically lower in parts of the hippocampus in MDD detected postmortem with in situ hybridization analysis (Lopez-Figueroa et al. 2004). Furthermore, in MDD subjects who had committed suicide, lower hippocampal 5-HT$_{1B}$ receptor (in female subjects) and p11 mRNA expression compared with controls was found (Anisman et al. 2008). In the same study, low 5-HT$_{1B}$ receptor and p11 mRNA expression was found in the frontopolar cortex. In the hypothalamus, by contrast, 5-HT$_{1B}$ Receptor mRNA expression was high in MDD suicide subjects (Anisman et al. 2008).

In the prefrontal cortex, 5-HT$_{1B}$ Receptor binding results so far have been negative, with no effect of MDD, neither in vivo with PET (Tiger et al. 2016) nor in membrane homogenates postmortem (Huang et al. 1999). Furthermore, in the basal ganglia, inconsistent findings have been reported in two PET studies. While Murrough et al. described low 5-HT$_{1B}$ receptor binding in the ventral striatum/ventral pallidum in MDD (Murrough et al. 2011b), we could not replicate this difference between MDD patients and controls (Tiger et al. 2016). However, the MDD populations in the two studies differed in a number of aspects, with the first study including subjects that were smoking, subjects with higher BMI, and a larger proportion of subjects with no previous exposure to antidepressant drugs, in contrast with the subjects of the latter study. There were also technical differences in the two studies, such as the use of different 5-HT$_{1B}$ receptor ligands, [¹¹C]P943 (Murrough et al. 2011b) and [¹¹C]AZ10419369 (Tiger et al. 2016), respectively, and different approaches in defining regions of interest (ROI), where Murrough et al. used a combined ROI from an automated template and we defined the ventral striatum and pallidum manually as separate ROIs. Perhaps most importantly, with the limited number of subjects in the two studies, there is a risk of type II errors, with failure to detect differences between MDD patients and controls due to low power.

In conclusion, low 5-HT$_{1B}$ Receptor binding and expression in ACC and hippocampus, key regions of the neurocircuitry of MDD (Mayberg 1997) has been reported.
**5-HT\textsubscript{1B} receptors and substance abuse**

Loss of control is a core feature in substance abuse disorders. Loss of 5-HT\textsubscript{1B} receptors in rodents induces a phenotype with reduced impulse control (Bouwknecht et al. 2001; Nautiyal et al. 2015). The involvement of 5-HT\textsubscript{1B} receptors in abuse has mainly been studied in relation to alcohol and cocaine, though there are also reports relating to amphetamine effects (Miszkiel et al. 2011) and pathological gambling (Potenza et al. 2013).

Alcohol consumption has been reported to be high in 5-HT\textsubscript{1B} receptor knockout mice (Crabbe et al. 1996). Correspondingly, low 5-HT\textsubscript{1B} receptor densities have been demonstrated with autoradiography in cingulate and retrosplenial cortices, septum, and amygdala in alcohol-prefering rats (McBride et al. 1997). Furthermore, 5-HT\textsubscript{1B} receptor agonists reduce alcohol self-administration in rats (Maurel et al. 1999; Tomkins and O’Neill 2000). On the other hand, overexpression of 5-HT\textsubscript{1B} receptors in the nucleus accumbens in rats lead to increased alcohol consumption (Hoplight et al. 2006). In humans, associations between the 5-HT\textsubscript{1B} receptor polymorphisms A161T in the 5′ regulatory region, with high reporter gene expression, and G681C and alcohol dependence (Sun et al. 2002) and antisocial alcoholism (Lappalainen et al. 1998), respectively, have been found. Additionally, high 5-HT\textsubscript{1B} receptor binding in the ventral striatum in subjects with alcohol dependence has been demonstrated with PET (Hu et al. 2010). However, no differences between alcoholic and control subjects in 5-HT\textsubscript{1B} receptor density in nucleus accumbens or any other examined brain region were found postmortem (Storvik et al. 2012). Furthermore, Huang et al. found no association between the 5-HT\textsubscript{1B} receptor gene polymorphism G861C and alcoholism (Huang et al. 2003). Thus, despite neatly consistent small animal model data, the role of 5-HT\textsubscript{1B} receptors in alcohol abuse remains unclear. This underscores the necessity of translational validation of animal model data in humans as a mandatory part of disease research.

Regarding 5-HT\textsubscript{1B} receptors and cocaine, mice lacking the receptor self-administer cocaine to a higher degree (Castanon et al. 2000; Rocha et al. 1998). However, inhibition of 5-HT\textsubscript{1B} receptors has either reduced or had no effect on cocaine self-administration (Miszkiel et al. 2011). When activating 5-HT\textsubscript{1B} receptors, the acquired effect on the reinforcing effects of cocaine has been reported to depend on the current state in relation to cocaine intake. 5-HT\textsubscript{1B} Receptor agonists and 5-HT\textsubscript{1B}Receptor gene transfer into the nucleus accumbens reduces cocaine-seeking behavior elicited by cocaine priming (Nair et al. 2013). The 5-HT\textsubscript{1B} receptor effect on cocaine reinforcement may relate to cocaine-induced receptor trafficking, as 5-HT\textsubscript{1B} Receptor mRNA increase in the dorsal striatum upon initiation of cocaine administration and decrease during abstinence (Neumaier et al. 2009). In humans,
low 5-HT$_{1B}$ receptor binding in vivo has indeed been described during abstinence not in striatum but in regions connected to the ventral striatum: anterior cingulate cortex, hypothalamus, and frontal cortex, in subjects with cocaine dependence (Matuskey et al. 2014).

**5-HT$_{1B}$ receptors and aggression**

An early and distinct finding in 5-HT$_{1B}$ receptor behavioral research has been its key role in regulating aggression, initially discovered through the enhanced aggressive behavior toward an intruder in 5-HT$_{1B}$ receptor knockout mice (Bouwknecht et al. 2001; Olivier et al. 1995; Saudou et al. 1994). Indeed, stimulation of 5-HT$_{1B}$ receptor signaling with the agonists CP 94,253, CP 93,129, and zolmitriptan administered intraperitoneally has been reported to induce marked serenic effects in mice (de Almeida et al. 2001; FacckiNodomo et al. 2008; FacckiNodomo et al. 2012; Fish et al. 1999; Rilke et al. 2001). However, in mice with a history of alcohol self-administration, CP 94,253 increased the number of bite attacks when injected into the medial prefrontal cortex after the mice had drunk a high dose of alcohol (FacckiNodomo et al. 2008). The 5-HT$_{1B}$ receptor-mediated aggression modulating effect may thus depend on the brain region, at least in alcohol-triggered aggressive behavior. Interestingly, Nautiyal et al. using a temporal receptor knockdown approach in mice demonstrated that forebrain 5-HT$_{1B}$ heteroreceptor expression during the postnatal period regulate the development of aggressive traits, while neither adult receptor rescue nor whole life autoreceptor knockdown had any effect on aggressive behavior (Nautiyal et al. 2015). In humans, a polymorphism for the 5-HT$_{1B}$ receptor genotype has been associated with childhood aggressive behavior and has been shown to influence the relationship between aggressive behavior during childhood and adult hostility (Hakulinen et al. 2013). Furthermore, in a recent PET study of violent offenders, psychopathy measurements and self-reported trait anger correlated with striatal 5-HT$_{1B}$ receptor binding, although not in the control group (da Cunha-Bang et al. 2016).

**Effects of antidepressive treatments on 5-HT$_{1B}$ receptors**

Studies on 5-HT$_{1B}$ receptors in relation to established treatments for depression provide a rich source of information on the potential role of the 5-HT$_{1B}$ receptor as a target for antidepressant treatment. SSRIs is the group of antidepressants most studied in the 5-HT$_{1B}$ receptor literature. In rats, time-dependent reduction of 5-HT$_{1B}$ receptor mRNA has been reported at time points corresponding to onset of antidepressive effect in clinical studies (Gelenberg and Chesen 2000; Neumaier et al. 1996). In a follow-up study, the SSRI-induced reduction of dorsal raphe 5-HT$_{1B}$ receptor mRNA expression was maintained after 8 weeks SSRI administration, but 5-HT$_{1B}$ Receptor mRNA levels were rapidly restored upon drug washout. Nortriptyline, however, had no effect on 5-HT$_{1B}$ mRNA expression (Anthony et al. 2000). Similarly, chronic fluoxetine administration reduced 5-HT$_{1B}$ receptor function in hippocampal and cortical neurons (Blier et al. 1988; Lifschytz et al. 2004) and induced downregulation of 5-HT$_{1B}$ receptors in suprachiasmatic nucleus in rats (O’Connor and Kruk 1994). Furthermore, in 5-HT$_{1B}$ receptor gene knockout mice, the SSRI effect on forced swimming test immobility was absent, suggesting 5-HT$_{1B}$ receptors as necessary for mediating the antidepressant effect of SSRI (Trillat et al. 1998). However, reduced depression-like behavior has been demonstrated with fluoxetine in 5-HT$_{1B}$ receptor knockout mice using another model of depression, the tail suspension test (Mayorga et al. 2001). Moreover, pharmacological 5-HT$_{1B}$ receptor inhibition reduced the mobility-enhancing effect of SSRI, but not of imipramine, in the forced swim test (Chenu et al. 2008). However, reduced anti-immobility time in the forced swim test with SSRI in combination with 5-HT$_{1B}$ receptor antagonists has also been reported (Tatarczynska et al. 2002). Moreover, in a similar study by the same group, no effect of combined administration of SSRI and 5-HT$_{1B}$ receptor antagonists on the forced swim test was found, although rats given 5-HT$_{1B}$ Receptor antagonists together with tricyclic antidepressants or a selective monoamine oxidase inhibitor displayed less immobility in the forced swimming test (Tatarczynska et al. 2004a). On the other hand, activation of 5-HT$_{1B}$ receptors with the agonists ansiptoline and RU 24969 potentiated the antidepressive-like effect of SSRIs as well as imipramine and noradrenaline reuptake inhibitors in the forced swim test in mice (David et al. 2001; Redrobe et al. 1996), albeit in the case of ansiptoline only in young, but not in old, mice. In humans, a marked reduction of zolmitriptan-induced rise in GH concentration has been reported in MDD patients after SSRI treatment, possibly due to downregulation of 5-HT$_{1B}$/1D receptors after SSRI (Whale et al. 2001). Furthermore, a polymorphism for the 5-HT$_{1B}$ receptor gene was associated with SSRI response in samples of depressed patients from the STAR*D study (Villafuerte et al. 2009). Moreover, early reduction of the functionally related protein p11 in natural killer cells and monocytes with SSRI treatment has been found to correlate with antidepressant response in patients with MDD (Svenningsson et al. 2014). Altogether, in most studies, reduction of 5-HT$_{1B}$ receptor expression and function has been reported with SSRIs, while paradoxically 5-HT$_{1B}$ receptor agonists consistently display antidepressant-like effects in animal models. One explanation could be that 5-HT$_{1B}$ receptors are internalized upon activation, leading to downregulation of 5-HT$_{1B}$ receptors, especially in the raphe nuclei neurons, which have relative few synapses and therefore are more sensitive to fluctuations.
in synaptic serotonin concentrations (Jacobs and Azmitia 1992).

Although the main body of research on antidepressants’ effect on 5-HT$_{1B}$ receptors consists of studies with SSRI, a number of other drugs used in the treatment of depression have been examined in relation to 5-HT$_{1B}$ receptors such as the tricyclic antidepressants and the monoamine oxidase inhibitor mentioned earlier in the text. Lithium, one of the most established drugs for the treatment of mood disorders, has been suggested to act through 5-HT$_{1B}$ receptors, based on its potentiating effects on 5-HT$_{1B}$ receptor agonists in the forced swimming test (Redrobe and Bourin 1999). Interestingly, in a study in rodent cortices and blood platelets from healthy human subjects, lithium in “therapeutic” concentrations relatively selectively and noncompetitively inhibited 5-HT$_{1B}$ receptor binding and actions, such as G-protein coupling and reduction of forskolin-induced cAMP release (Massot et al. 1999). Following up these results in a small group of depressed patients, Januel et al. described a similar blocking effect on 5-HT$_{1B}$ receptor-induced cAMP reduction with lithium treatment. Furthermore, the reduced adenylate cyclase activity inversely correlated with antidepressive treatment response (Januel et al. 2002), indicating 5-HT$_{1B}$ receptor involvement in lithium treatment effect. Lithium inhibits glycogen synthase kinase-3 (GSK3) activity (Stambolic et al. 1996). In a previous study, GSK3 inhibitors and molecular ablation of GSK3β abolished 5-HT$_{1B}$ receptor coupling to G$_{i/o}$ subunits and GSK3 inhibitors abolished 5-HT$_{1B}$ receptor-mediated inhibition of serotonin release in the mouse cortex (Chen et al. 2011). Thus, the regulation of 5-HT$_{1B}$ receptor function by lithium could possibly be mediated via GSK3 inhibition. However, 5-HT$_{1B}$ receptor involvement is not limited to the established antidepressants. In the most promising new line of MDD drug research, a glutamate α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-dependent increase in 5-HT$_{1B}$ receptor binding in the nucleus accumbens and ventral pallidum has been demonstrated in response to ketamine in nonhuman primates (Yamanaka et al. 2014).

In addition, a number of 5-HT$_{1B}$ receptor studies of other treatment modalities have been performed. Different brain stimulation regimes have been examined in rats. Reduced serotonin increase in response to the 5-HT$_{1B}$ receptor antagonist GR 127935 has been demonstrated with repetitive transcranial magnetic stimulation (Gur et al. 2000). Electroconvulsive shock (ECT), the animal model of electroconvulsive therapy (ECT), on the other hand, did not alter 5-HT$_{1B}$ autoreceptor-mediated action in the hypothalamus or hippocampus (Gur et al. 2002). However, a significant increase of the 5-HT$_{1B}$ receptor-related p11 has been demonstrated in the cortex after ECS (Svenningsson et al. 2006). In humans, the literature on brain 5-HT$_{1B}$ receptor response to treatment for depression is very limited. In the only 5-HT$_{1B}$ receptor PET study of MDD treatment published so far, a distinct reduction of 5-HT$_{1B}$ receptor binding in the dorsal brain stem, encompassing especially the median raphe nucleus, was observed after successful cognitive behavioral therapy (Tiger et al. 2014).

### Targeting the 5-HT$_{1B}$ receptor for antidepressant effect

The 5-HT$_{1B}$ receptor can be relatively labile in its expression, with rapid and region-specific changes in mRNA and protein expression in response to conditions such as stress (Neumaier et al. 1997), drug exposure (Anthony et al. 2000; Neumaier et al. 1996; Nord et al. 2013), and estrogen status (Hiroi and Neumaier 2009). This lability is probably an important factor in the diversity of behavioral responses that have been reported for pharmacological studies of this receptor. Sensitivity to stress and pharmacological manipulations makes the 5-HT$_{1B}$ receptor particularly interesting as a target for treatment of MDD, serving as a marker for state rather than trait. A multitude of drugs targeting the 5-HT$_{1B}$ receptor have demonstrated potential antidepressant properties. Which is then the most suitable approach to modulate 5-HT$_{1B}$ receptor activity in order to best treat depression?

Given the inhibitory effect of 5-HT$_{1B}$ receptors on serotonin release and the predominantly prevailing serotonin hypothesis of MDD, it makes sense to block 5-HT$_{1B}$ receptors for antidepressant effect (Slassi 2002). Thus far, most 5-HT$_{1B}$ receptor drug candidates for MDD treatment have been antagonists, such as SB-616234-A (Dawson et al. 2006), AZD3783 (Zhang et al. 2011), and AR-A000002 (Hudzik et al. 2003). It has been proposed that 5-HT$_{1}$ receptor activation counteracts the serotonin-enhancing effects of SSRI and thereby contributes to the latency of therapeutic effect (Blier and de Montigny 1994; Nutt 2002). SSRI-induced downregulation of 5-HT$_{1}$ receptors would then restore the serotonin-elevating effects of the drugs and hence enable a clinical effect, providing a rationale for blocking 5-HT$_{1B}$ receptors for rapid antidepressant response. However, the serotonin-releasing and reuptake inhibiting drug fenfluramine had no augmenting effect compared to placebo in patients with treatment refractory depression (Price et al. 1990), even though it is a far more potent serotonin enhancer than any SSRI (Rothman and Baumann 2002). Moreover, 5-HT$_{1B}$ receptor antagonists alone are likely not sufficiently effective as antidepressants, but likely have a potential as adjuvants in the treatment for depression (Ruf and Bhagwagar 2009). Hence, a combination of SSRI and 5-HT$_{1B}$ receptor antagonist has been introduced as a new antidepressant concept (Matzen et al. 2000).

If, on the other hand downregulation/desensitization of 5-HT$_{1B}$ autoreceptors rather is mediating the antidepressant effects of SSRI, agonists would constitute a rational treatment approach, promoting quicker and more selective...
downregulation of 5-HT$_{1B}$ receptors. Moreover, treating depression by stimulating forebrain 5-HT$_{1B}$ receptors would be in line with the low 5-HT$_{1B}$ receptor binding found in patients with MDD, especially in the limbic system, in areas of reported importance in the pathophysiology of depression (Mayberg 1997; Steele et al. 2007). Indeed, increased 5-HT$_{1B}$ receptor binding in serotonergic projection areas has been demonstrated in humans after a single, clinically relevant, dose of SSRI (Nord et al. 2013). Furthermore, there was a trend of increased 5-HT$_{1B}$ Receptor mRNA in projection areas after chronic SSRI administration in rats (Neumaier et al. 1996). Interestingly, in both humans and rats, 5-HT$_{1B}$ receptor measurements were reduced in raphe nuclei with SSRI (Neumaier et al. 1996; Nord et al. 2013). The increase in serotonin concentration with SSRI could thus primarily downregulate raphe nuclei 5-HT$_{1B}$ receptors due to the relatively low number of serotonergic synapses and therefore higher serotonin concentration in each synapse in this region (Jacobs and Azmitia 1992). This would, in theory, lead to increased serotonin release in projection areas and possibly upregulation of inhibitory 5-HT$_{1B}$ receptors in these regions, potentially counteracting the low 5-HT$_{1B}$ receptor levels earlier described in patients with MDD (Anisman et al. 2008; Murrough et al. 2011a; Murrough et al. 2011b; Tiger et al. 2016). Moreover, 5-HT$_{1B}$ receptor agonists have been proven successful in animal models for depression (see “Effects of agonists and antagonists in animal models of depression” section). However, treatment with 5-HT$_{1B}$ receptor agonists entail a potential risk of cognitive side effects, given the impaired spatial reference memory after 5-HT$_{1B}$ receptor agonist administration in rats and the superior spatial reference memory performance in 5-HT$_{1B}$ receptor gene knockout mice (Buhot et al. 2000; Woehrle et al. 2013).

In this sense, partial agonists offer an appealing alternative. Indeed, this concept has been successfully demonstrated in the treatment of depression with the partial 5-HT$_{1B}$ receptor agonist sertraline (Berhan and Barker 2014). However, vortioxetine also inhibits serotonin reuptake and exerts multiple serotonergic actions at additional receptor subtypes (Dhir and Sarvaiya 2014; Sanchez et al. 2015). Thus, it remains unknown whether the partial agonist effect at the 5-HT$_{1B}$ receptor represents a primary mechanism necessary for the antidepressant properties.

Finally, inverse agonism should also be an interesting approach, although to our knowledge currently no studies of the antidepressant effects of selective 5-HT$_{1B}$ receptor inverse agonists are available. In contrast with antagonists, 5-HT$_{1B}$ receptor inverse agonists can increase serotonin release per se, as demonstrated with the 5-HT$_{1B}$ receptor inverse agonist SB-236057-A in the hippocampus in guinea pigs (Roberts et al. 2001). The potential of this mode of action is underscored by the 5-HT$_{1B}$ receptor inverse agonist properties of lithium, outlined in “Effects of antidepressive treatments on 5-HT$_{1B}$ receptors” section. A drug which mimics the effect of lithium, hopefully without the nephrotoxic effects and narrow therapeutic interval of the latter, would be a major contribution to the treatment of mood disorders (Curran and Ravindran 2014; Nelson et al. 2014; Raja 2011).

**Conclusion**

The 5-HT$_{1B}$ receptor is a key protein in mice and men, modulating a number of physiological functions and behaviors through regulation of release of serotonin and a number of other neurotransmitters. The main body of the literature on 5-HT$_{1B}$ receptors in relation to depression consists of research in animals, although data from human studies on 5-HT$_{1B}$ receptor in MDD are slowly accumulating. The evidence summarized above supports a role of the 5-HT$_{1B}$ receptor as an interesting target for antidepressant treatment. However, it is not yet clear how to best alter 5-HT$_{1B}$ receptor binding and action, for optimal effect, although it could be argued that 5-HT$_{1B}$ receptor agonists have an advantage given the low 5-HT$_{1B}$ receptor binding described in MDD patients and the increase in 5-HT$_{1B}$ receptor binding with SSRI in humans, in serotonergic projection areas. So far, proof of concept for 5-HT$_{1B}$ receptor-mediated MDD treatment effect has been demonstrated for the partial 5-HT$_{1B}$ receptor agonist vortioxetine, although effects at additional 5-HT-binding sites likely contribute to the antidepressant effects of this compound. Future studies on the effect of established treatments for depression, such as antidepressants and ECT, on 5-HT$_{1B}$ receptor binding and action are needed to guide the process of developing drugs targeting the 5-HT$_{1B}$ receptor, with potential antidepressant effect. In the process of 5-HT$_{1B}$ receptor drug development, it is important to be aware of the well-characterized species differences in receptor pharmacology.

**Acknowledgements** The study was supported by the Swedish Society of Medicine, the Swedish Research Council (523-2013-2982), a donation by Birgitta and Sten Westerberg, the Stockholm Centre for Psychiatry Research, and Karolinska Institutet.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

Adell A, Celada P, Artigas F (2001) The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem 79:172–182

Adham N, Romanienko P, Hartig P, Weinshank RL, Brancheck T (1992) The rat 5-hydroxytryptamine1B receptor is the species homologue...
of the human 5-hydroxytryptamine1D beta receptor. Mol Pharmacol 41:1–7
Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113:296–320
Anisman H, Du L, Palkovits M, Faludi G, Kovacs GG, Szontagh-Kishazi P, Merali Z, Poulter MO (2008) Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J Psychiatry Neurosci 33:131–141
Anthony JP, Sexton TJ, Neumaier JF (2000) Antidepressant-induced regulation of 5-HT1B mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J Neurosci Res 61:82–87
Bagdy E, Kiraly I, Harsing LG Jr (2000) Reciprocal innervation between serotonergic and GABAergic neurons in raphe nuclei of the rat. Neurochem Res 25:1465–1473
Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38:1083–1152
Bechtholt AJ, Smith K, Gaughan S, Lucki I (2008) Sucrose intake and fasting glucose levels in 5-HT1A and 5-HT1B receptor mutant mice. Physiol Behav 93:659–665
Belmaker RH, Agam G (2008) Major depressive disorder. N Engl J Med 358:55–68
Berhan A, Barker A (2014) Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 14:276
Bidmon HJ, Schleicher A, Wicke K, Gross G, Zilles K (2001) Localisation of mRNAs for h5-HT1B and h5-HT1D receptors in human dorsal raphe. Naunyn Schmiedeberg's Arch Pharmacol 363:364–368
Blier P, Chaput Y, de Montigny C (1988) Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain. Naunyn Schmiedeberg's Arch Pharmacol 337:246–254
Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220–226
Bonaventure P, Schotte A, Cras P, Leyens JE (1997) Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]jalindutin, a new radioligand. Receptors Channels 5:225–230
Bonaventure P, Voom P, Luynen WH, Jurzak M, Schotte A, Leyens JE (1998) Detailed mapping of serotonin 5-HT1B and 5-HT1D receptor messenger RNA and ligand binding sites in guinea-pig brain and trigeminal ganglion: clues for function. Neuroscience 82:469–484
Boschert U, Amara DA, Segu L, Hen R (1994) The mouse 5-hydroxytryptamine1B receptor is localized predominantly on axon terminals. Neuroscience 58:167–182
Boshuisen ML, den Boer JA (2000) Zolmitriptan (a 5-HT1B/1D receptor 68 agonist) decreases the functional modulation of 5-HT1A receptors in rat brain. Naunyn Schmiedeberg's Arch Pharmacol 353:281–289
Boutrel B, Franc B, Hen R, Hamon M, Adrien J (1999) Key role of 5-HT1B receptors in the regulation of paradoxical sleep as evidenced in 5-HT1B knockout mice. J Neurosci 19:3204–3212
Bouwknegt JA, Hijzen TH, van der Gugten J, Maes RA, Hen R, Olivier B (2001) Absence of 5-HT1B receptors is associated with impaired impulse control in male 5-HT1B knockout mice. Biol Psychiatry 49:557–568
Brannon CR, Sollars PJ, Pickard GE, Dudek FE (2005) 5-HT1B receptor-mediated presynaptic inhibition of GABA release in the suprachiasmatic nucleus. J Neurophysiol 93:3157–3164
Brazell MP, Marsden CA, Nisbet AP, Routledge C (1985) The 5-HT1 receptor agonist RU-24969 decreases 5-hydroxytryptamine (5-HT) release and metabolism in the rat frontal cortex in vitro and in vivo. Br J Pharmocol 86:209–216
Bruinvels AT, Landwehrmeyer B, Gustafson EL, Durkin MM, Mengod G, Branchek TA, Hoyer D, Palacios JM (1994) Localization of 5-HT1B, 5-HT1D alpha, 5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain. Neuropharmacology 33:367–386
Bruinvels AT, Palacios JM, Hoyer D (1993) Autoradiographic characterisation and localisation of 5-HT1D compared to 5-HT1B binding sites in rat brain. Naunyn Schmiedeberg's Arch Pharmacol 347:569–582
Brunner D, Buhot MC, Hen R, Hofer M (1999) Anxiety, motor activation, and maternal-infant interactions in 5HT1B knockout mice. Behav Neurosci 113:587–601
Buhlen M, Fink K, Boing C, Gothert M (1996) Evidence for presynaptic location of inhibitory 5-HT1D beta-like autoreceptors in the guinea-pig brain cortex. Naunyn Schmiedeberg's Arch Pharmacol 353:281–289
Buhot MC, Martin S, Segu L (2000) Role of serotonin in memory impairment. Ann Med 32:210–221
Cassel JC, Jetsch S, Neufang B, Lauth D, Szabo B, Jackisch R (1995) Downregulation of muscarinic- and 5-HT1B-mediated modulation of [3H]acetylcholine release in hippocampal slices of rats with fimbria-fornix lesions and intrahippocampal grafts of septum origin. Brain Res 704:153–166
Castanon N, Scearce-Levie K, Lucas JJ, Rocha B, Hen R (2000) Modulation of the effects of cocaine by 5-HT1B receptors: a comparison of knockouts and antagonists. Pharmacol Biochem Behav 67:559–566
Chaouloff F, Courvoisier H, Moisan MP, Mormede P (1999) GR 127935 reduces basal locomotor activity and prevents RU 24969, but not D-amphetamine-induced hyperlocomotion, in the Wistar-Kyoto hyperactive (WKHA) rat. Psychopharmacology 141:326–331
Cheetham SC, Heal DJ (1993) Evidence that RU 24969-induced locomotor activity in C57/B1/6 mice is specifically mediated by the 5-HT1B receptor. Br J Pharmacol 110:1621–1629
Chen L, Yung KK, Chan YS, Yung WH (2008) 5-HT excites globus pallidus neurons by multiple receptor mechanisms. Neuroscience 151:439–451
Chen L, Zhou W, Chen PC, Gaisina I, Yang S, Li X (2011) Glycogen synthase kinase-3beta is a functional modulator of serotonin-1B receptors. Mol Pharmacol 79:974–986
Chenu F, David DJ, Leroux-Nicollet I, Le Maitre E, Gardier AM, Bourin M (2008) Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J Psychiatry Neurosci 33:541–550
Chojnacka-Wojcik E, Klodzinska A, Tatarczynska E (2005) The anxiolytic-like effect of 5-HT1B receptor ligands in rats: a possible mechanism of action. J Pharm Pharmacol 57:253–257
Clark MS, Sexton TJ, McClain M, Root D, Cohen R, Neumaier JF (2002) Overexpression of 5-HT1B receptor in dorsal raphe nucleus using herpes simplex virus gene transfer increases anxiety behavior after inescapable stress. J Neurosci 22:4550–4562
Cleare AJ, Murray RM, Sherwood RA, O'Keane V (1998) Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan. Psychol Med 28:295–300
Clementy Y, Kia KH, Daval G, Verge D (1996) An autoradiographic study of serotonergic receptors in a murine genetic model of anxiety-related behaviors. Brain Res 709:229–242
Coman V, Segu L, Buhot MC, Daszuta A (1998) Differential effects of serotonin (5-HT) lesions and synthesis blockade on neuropeptide-Y immunoreactivity and 5-HT1A, 5-HT1B, and 5-HT2A receptors in rat brain. Brain Res 795:264–76
Crabbe JC, Phillips TJ, Feller DJ, Hen R, Wenger CD, Leson CN, Schafer GL (1996) Elevated alcohol consumption in null mutant mice lacking 5-HT1B serotonin receptors. Nat Genet 14:98–101
Curran G, Ravindran A (2014) Lithium for bipolar disorder, a review of the recent literature. Expert Rev Neurother 14:1079–1098
da Cunha-Bang S, Hjordt LV, Perlalk E, Believe V, Bock C, Lelah S, Thomsen C, Sestoff D, Svarer C, Knudsen GM (2016) Serotonin1B receptor binding is associated with trait anger and level of psychopathy in violent offenders. Biol Psychiatry
David DJ, Bourin M, Hascoet M, Colombel MC, Baker GB, Jolliet P (2001) Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5-HT1B receptors in old mice. Psychopharmacology 153:433–449

Davidson C, Stamford JA (1995) Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors. Br J Pharmacol 114:1107–1109

Dawson LA, Hughes ZA, Starr KR, Storey JD, Bettelini L, Bacchi F, de Groote L, Olivier B, Westenberg HG (2003) Role of 5-HT1B receptors in alcohol drinking in male mice. Psychopharmacology 165:1–11

De Almeida RM, Nikulina EM, Facicidomo S, Fish EW, Miczek KA (2001) Zolmitriptan—a 5-HT1B/D agonist, alcohol, and aggression in mice. Psychopharmacology 157:131–141

De Groote L, Olivier B, Westenberg HG (2003) Role of 5-HT1B receptors in the regulation of extracellular serotonin and dopamine in the dorsal striatum of mice. Eur J Pharmacol 476:71–77

De Rezende MG, Garcia-Leal C, Graeff FG, Del-Ben CM (2013) The 5-HT1B receptor agonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2-met-hyI-4′-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl-4-yl](methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology 50:975–983

De Almeida RM, Nikulina EM, Facicidomo S, Fish EW, Miczek KA (2001) Zolmitriptan—a 5-HT1B/D agonist, alcohol, and aggression in mice. Psychopharmacology 157:131–141

De Groote L, Olivier B, Westenberg HG (2003) Role of 5-HT1B receptors in the regulation of extracellular serotonin and dopamine in the dorsal striatum of mice. Eur J Pharmacol 476:71–77

De Rezende MG, Garcia-Leal C, Graeff FG, Del-Ben CM (2013) The 5-HT1B receptor agonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2-met-hyI-4′-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl-4-yl](methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology 50:975–983

Fish EW, Facicidomo S, Miczek KA (1999) Aggression heightened by alcohol or social instigation in mice: reduction by the 5-HT(1B) receptor agonist CP-94,253. Psychopharmacology 146:391–399

Gelenberg AJ, Chesin CL (2000) How fast are antidepressants? J Clin Psychiatry 61:712–721

Girard C, Tinel N, Terrenoire C, Romey G, Ladunski M, Borsotto M (2002) p11, an annexin II subunit, an auxiliary protein associated with the background K+ channel, TASK-1. EMBO J 21:4439–4448

Giuliano F (2007) 5-Hydroxytryptamine in premature ejaculation: opportunities for therapeutic intervention. Trends Neurosci 30:79–84

Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J (2004) Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 50:200–205

Guo JD, Rainnie DG (2010) Presynaptic 5-HT(1B) receptor-mediated serotonin inhibition of glutamate transmission in the bed nucleus of the stria terminals. Neuroscience 165:139–140

Gur E, Drenencov E, Garcia F, Van de Karren L, Rener B, Newman ME (2002) Functional effects of chronic electroconvulsive shock on serotonergic 5-HT(1A) and 5-HT(1B) receptor activity in rat hippocampus and hypothalamus. Brain Res 952:52–60

Gur E, Rener B, Drenencov E, Newman ME (2000) Chronic repetitive transcranial magnetic stimulation induces subsensitivity of presynaptic serotonergic autoreceptor activity in rat brain. Neuroreport 11:2925–2929

Hagan CE, McDevitt RA, Liu Y, Furay AR, Neumaier JF (2012) 5-HT(1B) autoreceptor regulation of serotonin transporter activity in synaptosomes. Synapse 66:1024–1034

Hagan JJ, Slade PD, Gaster L, Jeffrey P, Hatcher JP, Midlem & NN (1997) Stimulation of 5-HT1B receptors causes hypertrophia in the guinea pig. Eur J Pharmacol 331:169–174

Hakulinen C, Jokela M, Hintsanen M, Merjonen P, Pulkki-Raback L, Seppala I, Lyytikainen LP, Lehtimaki T, Kahonen M, Viikari J, Raitakari OT, Keltikangas-Jarvinen L (2013) Serotonin receptor 1B genotype and hostility, anger and aggressive behavior through the lifespan: the Young Finns study. J Behav Med 36:583–590

Hall H, Lundkvist C, Halldin C, Farde L, Pike VW, McCarron JA, Fletcher A, Cliffe JA, Barf T, Wickstrom H, Sedvall G (1997) Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635. Brain Res 745:96–108

Hallidin C, Gulyas B, Langer O, Farde L (2001) Brain radioligands—state of the art and new trends. Q J Nucl Med 45:139–152

Hamblin MW, Ariani K, Adriaenssens PI, Ciarnellod RD (1987) [3H] dihydroergotamine as a high-affinity, slowly dissociating radioligand for 5-HT1B binding sites in rat brain membranes: evidence for guanine nucleotide regulation of agonist affinity states. J Pharmacol Exp Ther 243:989–1001

Hamblin MW, Metcalf MA, McGuinness RW, Carpells S (1992) Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. Biochem Biophys Res Commun 184:752–759

Hashimoto K, Kita H (2008) Serotonin activates presynaptic and postsynaptic receptors in rat globus pallidus. J Neurophysiol 99:1723–1732

Hiroi R, Neumaier JF (2009) Estrogen decreases 5-HT1B autoreceptor mRNA in selective subregion of rat dorsal raphe nucleus: inverse association between gene expression and anxiety behavior in the open field. Neuroscience 158:456–464

Hjorth S, Tao R (1991) The putative 5-HT1B receptor agonist CP-93,129 suppresses rat hippocampal 5-HT release in vivo: comparison with RU 24969. Eur J Pharmacol 209:249–252

Ho EV, Thompson SL, Katza WR, Sharifi MF, Knowles JA, Dulawac SC (2016) Clinically effective OCD treatment prevents 5-HT1B

Springer
Hoplight BJ, Sandygren NA, Neumaier JF (2006) Increased expression of 5-HT1B receptors in rat nucleus accumbens via virally mediated gene transfer increases voluntary alcohol consumption. Alcohol 38:73–79
Hoplight BJ, Vincow ES, Neumaier JF (2005) The effects of SB 224289 on anxiety and cocaine-related behaviors in a novel object task. Physiol Behav 84:707–714
Horwitz A, Wakefield J (2007) The loss of sadness—how psychiatry transformed normal sorrow into depressive disorder. Oxford University Press, Oxford
Hoyer D, Hannon JP, Martin GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmaco Biochem Behav 71:533–554
Hu J, Henry S, Gallezot JD, Ropchan J, Neumaier JF, Potenza MN, Sinha R, Krystal JH, Huang Y, Ding YS, Canson RE, Neumeister A (2010) Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry 67:800–803
Hu XJ, Wang FH, Stenfors C, Ogren SO, Kehr J (2007) Effects of the 5-HT1B receptor antagonist RS67519 on extracellular levels of acetylecholine, glutamate and GABA in the frontal cortex and ventral hippocampus of awake rats: a microdialysis study. Eur Neuropsychopharmacol 17:580–586
Huang YY, Grailhe R, Arango V, Hen R, Mann JJ (1999) Relationship of psychopathology to the human serotonin1B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology 21:238–246
Huang YY, Oquendo MA, Friedman JM, Greenhill LL, Brodsky B, Malone KM, Khait V, Mann JJ (2003) Substance abuse disorder and major depression are associated with the human 5-HT1B receptor gene (HTR1B) G861C polymorphism. Neuropsychopharmacology 28:163–169
Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M, Lifschytz T, Broner EC, Zozulinsky P, Slonimsky A, Eitan R, Greenbaum L, Bler L (2012) Relationship between Rgs2 gene expression level and anxiety and depression-like behaviour in a mutant mouse model: serotonergic involvement. Int J Neuropsychopharmacol 15:1307–1318
Lifschytz T, Gür E, Lerer B, Newman ME (2004) Effects of triiodothyronine and fluoroxetine on 5-HT1A and 5-HT1B autoreceptor activity in rat brain: regional differences. J Neurosci Methods 130:133–139
Lemire N, Deicher R, Starke K (1991) Species differences in presynaptic serotonin autoreceptors: mainly 5-HT1B but possibly in addition 5-HT1D in the rat, 5-HT1D in the rabbit and guinea-pig brain cortex. Naunyn Schmiedebergs Arch Pharmacol 343:353–364
Lin D, Parsons LH (2002) Anxiogenic-like effect of serotonin (1B) receptor stimulation in the rat elevated plus-maze. Pharmacol Biochem Behav 71:581–587
Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, Lopez-JF, Watson SJ (2004) Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 55:225–233
Malgue I, Trillat AC, Bourin M, Jacquot C, Hen R, Gardier AM (2001) 5-HT1B autoreceptors limit the effects of selective serotonin reuptake inhibitors in mouse hippocampus and frontal cortex. J Neurochem 76:865–871
Maroteaux L, Saudou F, Amlaiky N, Boschart U, Plassat JL, Hen R (1992) Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A 89:3020–3024
Martin KF, Hannon S, Phillips I, Heal DJ (1992) Opposing roles for 5-HT1A and 5-HT3 receptors in the control of 5-HT release in rat hippocampus in vivo. Br J Pharmacol 106:139–142
Mats S, Pagerols M, Gasso P, Ortiz A, Rodriguez N, Morer A, Plana MT, Lafuente A, Lazaro L (2014) Role of GAD2 and HTR1B genes in early-onset obsessive-compulsive disorder: results from transmission disequilibrium study. Genes Brain Behav 13:409–417
